|
|
|
| TERAZOSIN HYDROCHLORIDE | ||
|
PRODUCT IDENTIFICATION |
||
| CAS NO. | 70024-40-7 |
|
| EINECS NO. | ||
| FORMULA | C19H25N5O4·HCl | |
| MOL WT. | 423.90 | |
|
H.S. CODE |
||
|
TOXICITY |
|
|
| SMILES |
|
|
| SYNONYMS | ||
| (RS)-1-(4-amino-6,7-dimethoxy-2-quinazolinyl) -4-[(tetra-hydro-2-furanyl) carbonyl]- piperazine monohydrochloride. | ||
|
SMILES |
||
|
PHYSICAL AND CHEMICAL PROPERTIES |
||
| PHYSICAL STATE | white crystalline powder | |
| MELTING POINT | 215 - 217 C | |
| BOILING POINT | ||
| SPECIFIC GRAVITY | ||
| SOLUBILITY IN WATER | Soluble | |
| pH | ||
| VAPOR DENSITY |
|
|
| AUTOIGNITION |
|
|
| NFPA RATINGS |
|
|
|
REFRACTIVE INDEX |
||
| FLASH POINT |
|
|
| STABILITY |
Stable under ordinary conditions |
|
|
APPLICATIONS |
||
| Terazosin, alpha-1-adrenergic blockers, used in the treatment of hypertension by relaxing veins and arteries so that blood can flow more easily and to treat benign prostatic hyperplasia (BPH) by relaxing the muscles of the bladder and prostate. High blood pressure increases the workload of the heart and arteries, which damages the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart attack, or kidney failure. These risks may be less likely to occur if blood pressure is controlled. The hydrochloride salt of terazosin is a white, crystalline powder; freely soluble in water and isotonic saline; melting point 260 - 262 C; administered orally. Chemical designation is (RS)-1-(4-amino-6,7-dimethoxy-2-quinazolinyl) -4-[(tetra-hydro-2-furanyl) carbonyl]-piperazine monohydrochloride. | ||
| SALES SPECIFICATION | ||
|
APPEARANCE |
white crystals | |
|
IDENTIFICATION |
Complies Test A,B |
|
| ASSAY |
99.0% min |
|
|
LOSS ON DRYING |
1.0% max |
|
|
RELATED SUBSTANCE |
0.5% max |
|
|
HEAVY METALS |
20ppm max |
|
| SULFATED ASH |
0.1% max |
|
| TRANSPORTATION | ||
| PACKING |
|
|
| HAZARD CLASS | ||
| UN NO. | ||
| OTHER INFORMATION | ||
| Hazard Symbols: n/a, Risk Phrases: 42/43, Safety Phrases: 22-36/37-45 | ||
| PRICE INFORMATION |
||
 |
||
|
|
|
 |
